<DOC>
	<DOCNO>NCT00270400</DOCNO>
	<brief_summary>The purpose study compare effect heart rate ventricular arrhythmia ( irregular heart beat ) two dos NatrecorÂ® ( recombinant form natural human peptide normally secrete heart response heart failure ) versus dobutamine , first 24 hour treatment decompensated congestive heart failure ( CHF ) .</brief_summary>
	<brief_title>A Safety Study Comparing Natrecor ( Nesiritide ) Versus Dobutamine Therapy Worsening Congestive Heart Failure</brief_title>
	<detailed_description>Advanced congestive heart failure ( CHF ) account one million hospital admission yearly U.S. associate 2-year mortality rate 40 % - 50 % ( accord American Heart Association 1997 CONSENSUS Trial Study Group , 1987 ) . Inpatient therapy acutely worsen CHF often include intravenous ( IV ) agent reduce intracardiac filling pressure increase cardiac output . Examples agent include drug increase heart muscle contractility dobutamine phosphodiesterase inhibitor milrinone . While agent achieve good blood flow throughout body patient , several study suggest arrhythmia ( irregular heart beat ) increase patient treated dobutamine milrinone ( accord Smith TW , et al 1997 Holmes JR et al 1985 ; Anderson JL et al 1986 ) . Arrhythmias common patient advanced CHF may contribute sudden death rate 30 % 70 % ( accord Stevenson WG , et al 1993 ) . Holter monitor patient CHF show 90 % premature ventricular contraction non-sustained ventricular tachycardia ( rapid beating ) show 60 % patient ( accord Stevenson WG , et al 1994 ) atrial fibrillation approximately 20 % patient ( accord Smith TW , et al 1997 ) . The occurrence arrhythmia may associate decrease ventricular performance , may worsen symptom acutely decompensated CHF complicate patient management . The ventricle heart 's pump chamber pump oxygen-poor blood return body artery lung , blood pick oxygen . In atrial fibrillation heart 's two small upper chamber ( atrium ) quiver instead beat effectively . Therefore , imperative new therapy develop treatment decompensated CHF associate development increase arrhythmia . Natrecor® study IV treatment decompensated CHF 500 patient . As interstitial fluid ( lung tissue ) accumulate advanced CHF case , pulmonary capillary wedge pressure ( PCWP ) increase . However administration continuous IV infusion Natrecor® result dose-related decrease PCWP , right atrial pressure , systemic vascular resistance , increase cardiac index measurement volume blood pump heart , ( accord Marcus LS , Hart D , Packer M , et al 1996 ; Abraham WT al 1998 ; Mills RM et al 1999 ) . Beneficial improve blood flow throughout body associate decrease systolic blood pressure - heart rate index ( double product ) , suggest Natrecor® improve cardiac performance increase estimate myocardial oxygen consumption . The primary objective study compare effect heart rate ventricular arrhythmia two dos Natrecor® dobutamine , first 24 hour treatment decompensated CHF . The primary outcome study evaluation : ( 1 ) average heart rate , ( 2 ) average hourly premature ventricular beat , ( 3 ) average hourly repetitive beat , express change baseline , measure Holter monitoring ( portable device provide continuous monitor electrical activity heart ) . Additional objective include explore effect Natrecor® dobutamine Holter outcome couplet , triplet , ventricular tachycardia evaluation ventricular ectopy ( seven single premature ventricular beat per minute run two ventricular ectopic beat ) application specific proarrhythmic criterion . Clinical symptom also measure . This multicenter , randomize , open-label , active-controlled safety study design enroll approximately 240 patient symptomatic ( New York Heart Association [ NYHA ] Class III IV ) , decompensated CHF treatment dobutamine Natrecor® deem appropriate . After 24-Hour Baseline Holter Monitoring Period , patient randomize dobutamine Natrecor® ( 0.015 0.03 µg/kg/min ) . The randomization stratify whether subject know history Ventricular Tachycardia ( non-sustained sustain ) . Treatment assignment open-label regard study drug ( dobutamine Natrecor® ) ; assignment two Natrecor® dose group double-blinded . Dobutamine administer dose least 6 µg/kg/min . During first 24 hour study drug , patient undergoes Holter monitoring . Study drug ( dobutamine Natrecor® ) administer least 24 hour single IV vasoactive agent symptomatic , decompensated CHF . Other IV vasoactive agent milrinone , nitroprusside , nitroglycerin , and/or dose dopamine add study drug first 24 hour therapy . Dobutamine add Natrecor® infusion first 24 hour therapy . After 24 hour , Holter monitor remove , patient remain study drug , appropriate . Natrecor® patient continue fixed-dose Natrecor® regimen ( still blind specific dose group assignment ) maximum 7 day ( without addition parenteral agent ) switch whatever treatment appropriate , discretion investigator . Patients dobutamine treatment group continue study drug long appropriate , discretion investigator . Systemic hemodynamics ( blood pressure heart rate ) assess baseline , 15 30 minute , 3 , 8 , 16 , 24 hour follow initiation study drug . The study hypothesis Natrecor® associate increase report ventricular arrhythmia patient treat symptomatic decompensated CHF . Continuous IV ( intravenous ) Infusion least 24 hour , 24 hour discretion Principal Investigator . Dobutamine start 5 mcg/kg/min , may increase ; Natrecor® , either 0.015 mcg/kg/min 0.030 mcg/kg/min fix dose least 24 hour , maximum 7 day .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Dobutamine</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>History NYHA ( New York Heart Association ) Class III IV congestive heart failure ( CHF ) Has symptomatic , decompensated CHF inpatient therapy either dobutamine Natrecor® , administer single intravenous vasoactive agent ( drug influence tone caliber blood vessel ) without diuretic , deem appropriate Receiving stable dos oral antiarrhythmic medication ( medication help regulate irregular heart beat ) least 48 hour start study drug , receive antiarrhythmic medication . Can tolerate 24Hour Baseline Holter Monitoring Period without intravenous vasoactive medication , and/or tolerate specify washout period ( applicable ) intravenous vasoactive medication start baseline Holter monitoring Has systolic blood pressure consistently &lt; 85 mm Hg , cardiogenic shock , evidence significant hemodynamic instability require immediate institution inotropic/pressor support Has clinical condition expect require therapy one intravenous vasoactive agent Dopamine 24Hour Treatment Holter Monitoring Period Has receive treatment Dopamine intravenous vasoactive medication Dobutamine , Milrinone , Nitroprusside intravenous Nitroglycerin 4 hour current episode decompensated CHF related illness Requires intravenous antiarrhythmic medication 48 hour start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Renal Dysfunction</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Heart Decompensation</keyword>
	<keyword>Dyspnea Paroxsymal .</keyword>
</DOC>